{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:44:54Z","timestamp":1790441094372,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Genet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Countries in the Global North use biochemical tests to screen for at least 20 diseases in newborns, while in the UK, only 10 diseases are screened for. The United Kingdom National Screening Committee (UKNSC) is the entity responsible for making recommendations to the government with regards to which conditions should be included in the Newborn Screening (NBS) programme. Examination of the meeting minutes of the UKNSC between 2015 and 2022 revealed that no new diseases were recommended for NBS during this period. If there was no \u2018effective treatment\u2019 for the disease it was rejected for NBS. In 2022, the Newborn Genomes Programme (NGP) was announced; a research study aiming to screen for over 223 rare genetic diseases using whole genome sequencing technology in newborns. While this could lead to a seismic expansion of NBS in the UK, many of the diseases included in the programme are currently considered \u2018actionable\u2019 rather than \u2018treatable\u2019 conditions. This poses an ethical conundrum for the UKNSC, which is involved in both NBS and NGP, given that it has thus far made recommendations against the expansion of the NBS programme using available biochemical assays, contrary to what has been implemented in other countries in the Global North. In this paper, we aim to critically examine the processes and circumstances that have held back the expansion of the NBS programme in the UK, as compared with other countries, focusing on the period 2015\u20132022, when no new diseases were added to the UK NBS programme, and contrast them with the drivers that have led to the support and funding for the NGP during this same time.<\/jats:p>","DOI":"10.1007\/s12687-025-00788-1","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T05:52:52Z","timestamp":1749621172000},"page":"589-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The UK National screening committee, the newborn genomes programme, and the ethical conundrum for UK newborn screening"],"prefix":"10.1007","volume":"16","author":[{"given":"Sara M.","family":"Rankin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Marskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Machin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"788_CR1","unstructured":"All Wales Medical Genomics Service (2019) Wales Infants\u2019 & Children\u2019s Genome Service Available at: https:\/\/medicalgenomicswales.co.uk\/index.php\/health-professional-information\/wings"},{"key":"788_CR2","unstructured":"Bell J (2019) Drug companies pay for exclusive access to UK genetic data. Available at: https:\/\/www.biopharmadive.com\/news\/uk-biobank-genome-sequencing-investment-amgen-astrazeneca-johnson-gsk\/562709\/. Accessed 2024."},{"key":"788_CR3","doi-asserted-by":"crossref","unstructured":"Bessey A, Chilcott J, Pandor A et al (2020) The Cost-Effectiveness of expanding the UK newborn bloodspot screening programme to include five additional inborn errors of metabolism. Int J Neonatal Screen 6(4)","DOI":"10.3390\/ijns6040093"},{"issue":"5","key":"788_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/jimd.12750","volume":"47","author":"IR Betzler","year":"2024","unstructured":"Betzler IR, Hempel M, Mutze U et al (2024) Comparative analysis of gene and disease selection in genomic newborn screening studies. J Inherit Metab Dis 47(5):945\u2013970","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"788_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ajmg.c.31874","volume":"187","author":"D Bick","year":"2021","unstructured":"Bick D, Bick SL, Dimmock DP et al (2021) An online compendium of treatable genetic disorders. Am J Med Genet C Semin Med Genet 187(1):48\u201354","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"7990","key":"788_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41586-023-03763-3","volume":"624","author":"E Callaway","year":"2023","unstructured":"Callaway E (2023) World\u2019s biggest set of human genome sequences opens to scientists. Nature 624(7990):16\u201317","journal-title":"Nature"},{"key":"788_CR7","unstructured":"Carlie Driscoll C, McPherson B (2010) Newborn screening systems: the complete perspective"},{"issue":"9","key":"788_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1177\/0883073808318062","volume":"23","author":"AK Chedrawi","year":"2008","unstructured":"Chedrawi AK, Ali A, Al Hassnan ZN et al (2008) Profound biotinidase deficiency in a child with predominantly spinal cord disease. J Child Neurol 23(9):1043\u20131048","journal-title":"J Child Neurol"},{"key":"788_CR9","first-page":"100001","volume":"1","author":"CCY Chung","year":"2020","unstructured":"Chung CCY, Leung GKC, Mak CCY et al (2020) Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. Lancet Reg Health West Pac 1:100001","journal-title":"Lancet Reg Health West Pac"},{"key":"788_CR10","unstructured":"Commonwealth of Australia - Department of Health and Aged Care (2023) Newborn bloodspot screening. Available at: https:\/\/www.health.gov.au\/our-work\/newborn-bloodspot-screening"},{"key":"788_CR11","volume-title":"Newborn screening for biotinidase deficiency: an evidence map on screening for biotinidase deficiency for the UK National screening committee. Reportno. Report number|,| number|, date","author":"Costello Medical","year":"2021","unstructured":"Costello Medical (2021) Newborn screening for biotinidase deficiency: an evidence map on screening for biotinidase deficiency for the UK National screening committee. Reportno. Report number|,| number|, date. Institution|, Place Published|"},{"issue":"9","key":"788_CR12","first-page":"777","volume":"45","author":"R Dahiphale","year":"2008","unstructured":"Dahiphale R, Jain S, Agrawal M (2008) Biotinidase deficiency. Indian Pediatr 45(9):777\u2013779","journal-title":"Indian Pediatr"},{"key":"788_CR13","unstructured":"Davies CS (2016) Annual Report of the Chief Medical Officer 2016. Reportno. Report Number|, Date. Place Published|: Institution|"},{"key":"788_CR14","doi-asserted-by":"publisher","first-page":"914338","DOI":"10.3389\/fphar.2022.914338","volume":"13","author":"J Delaye","year":"2022","unstructured":"Delaye J, Cacciatore P, Kole A (2022) Valuing the burden and impact of rare diseases: A scoping review. Front Pharmacol 13:914338","journal-title":"Front Pharmacol"},{"issue":"5","key":"788_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ajhg.2020.10.003","volume":"107","author":"DP Dimmock","year":"2020","unstructured":"Dimmock DP, Clark MM, Gaughran M et al (2020) An RCT of rapid genomic sequencing among seriously ill infants results in high clinical utility, changes in management, and low perceived harm. Am J Hum Genet 107(5):942\u2013952","journal-title":"Am J Hum Genet"},{"issue":"Pt 1","key":"788_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1258\/acb.2007.007127","volume":"45","author":"M Downing","year":"2008","unstructured":"Downing M, Pollitt R (2008) Newborn bloodspot screening in the UK\u2013past, present and future. Ann Clin Biochem 45(Pt 1):11\u201317","journal-title":"Ann Clin Biochem"},{"key":"788_CR17","volume-title":"Juggling care and daily life: the balancing act of the rare disease community. Reportno. Report number|,| number|, date","author":"European Organisation for Rare Diseases","year":"2017","unstructured":"European Organisation for Rare Diseases (2017) Juggling care and daily life: the balancing act of the rare disease community. Reportno. Report number|,| number|, date. Institution|, Place Published|"},{"key":"788_CR18","volume-title":"Key principles for newborn screening. Reportno. Report number|,| number|, date","author":"European Organisation for Rare Diseases","year":"2021","unstructured":"European Organisation for Rare Diseases (2021) Key principles for newborn screening. Reportno. Report number|,| number|, date. Institution|, Place Published|"},{"issue":"6","key":"788_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajmg.a.61124","volume":"179","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR (2019) The burden of rare diseases. Am J Med Genet A 179(6):885\u2013892","journal-title":"Am J Med Genet A"},{"issue":"4","key":"788_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/eahr.500022","volume":"41","author":"P Friesen","year":"2019","unstructured":"Friesen P, Yusof ANM, Sheehan M (2019) Should the decisions of institutional review boards be consistent?? Ethics Hum Res 41(4):2\u201314","journal-title":"Ethics Hum Res"},{"key":"788_CR21","volume-title":"Fixing the present Building for the Future - Newborn screening for rare conditions. Reportno. Report number|,| number|, date","author":"UK Genetic Alliance","year":"2019","unstructured":"Genetic Alliance UK (2019) Fixing the present Building for the Future - Newborn screening for rare conditions. Reportno. Report number|,| number|, date. Institution|, Place Published|"},{"key":"788_CR22","unstructured":"Genomics England (2021) New public dialogue finds support for the use of whole genome sequencing in newborn screening \u2013 providing that the right safeguards and resources are in place 8 Jul 2021. Available at: https:\/\/www.genomicsengland.co.uk\/news\/public-dialogue-genomics-newborn-screening"},{"key":"788_CR23","unstructured":"Genomics England (2023a) Conditions List Available at: https:\/\/www.genomicsengland.co.uk\/initiatives\/newborns\/choosing-conditions\/conditions-list-generation-study"},{"key":"788_CR24","unstructured":"Genomics England (2023b) Newborn Genomes Programme Available at: https:\/\/www.genomicsengland.co.uk\/initiatives\/newborns\/choosing-conditions?chapter=principle-d. Accessed 2023."},{"key":"788_CR26","unstructured":"Genomics England (2023d) Newborn Genomes Programme - Ethics Available at: https:\/\/www.genomicsengland.co.uk\/initiatives\/newborns\/ethics. Accessed 30\/11\/2023."},{"key":"788_CR27","unstructured":"Genomics England (2025) The story behind us and The 100,000 Genomes Project. Available at: https:\/\/www.genomicsengland.co.uk\/about-us\/origins"},{"key":"788_CR25","unstructured":"Genomics England (2023c) Newborn Genomes Programme. Available at: https:\/\/www.genomicsengland.co.uk\/initiatives\/newborns"},{"issue":"3","key":"788_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10995-015-1869-9","volume":"20","author":"AJ Goldenberg","year":"2016","unstructured":"Goldenberg AJ, Comeau AM, Grosse SD et al (2016) Evaluating harms in the assessment of net benefit: A framework for newborn screening condition review. Matern Child Health J 20(3):693\u2013700","journal-title":"Matern Child Health J"},{"issue":"12","key":"788_CR29","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/jamapediatrics.2021.3496","volume":"175","author":"NIS Group","year":"2021","unstructured":"Group NIS, Krantz ID, Medne L et al (2021) Effect of Whole-Genome sequencing on the clinical management of acutely ill infants with suspected genetic disease: A randomized clinical trial. JAMA Pediatr 175(12):1218\u20131226","journal-title":"JAMA Pediatr"},{"key":"788_CR30","unstructured":"Health Resources and Services Administration - Advisory Committee on Heritable Disroders in Newborns and Children (2023) Recommended Uniform Screening Panel"},{"key":"788_CR31","volume-title":"Implications of whole genome sequencing for newborn screening. Reportno. Report number|,| number|, date","author":"Hopkins Van Mil","year":"2021","unstructured":"Hopkins Van Mil (2021) Implications of whole genome sequencing for newborn screening. Reportno. Report number|,| number|, date. Institution|, Place Published|"},{"key":"788_CR32","first-page":"e2","volume":"1","author":"R Horton","year":"2023","unstructured":"Horton R, Lucassen A (2023) Ethical issues Raised by new genomic technologies: the case study of newborn genome screening. Camb Prism Precis Med 1:e2","journal-title":"Camb Prism Precis Med"},{"issue":"11","key":"788_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/humu.24466","volume":"43","author":"J Jezkova","year":"2022","unstructured":"Jezkova J, Shaw S, Taverner NV et al (2022) Rapid genome sequencing for pediatrics. Hum Mutat 43(11):1507\u20131518","journal-title":"Hum Mutat"},{"key":"788_CR34","unstructured":"Joynson C (2021) Embedding ethics at the UK National Screening Committee. Available at: https:\/\/phescreening.blog.gov.uk\/2021\/03\/23\/embedding-ethics-at-the-uk-national-screening-committee\/"},{"key":"788_CR35","unstructured":"Jungner G, Wilson JMG (1966) Principles and Practice of Screening for Disease World Health Organization, Geneva, 1968"},{"issue":"2","key":"788_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/gim.2013.98","volume":"16","author":"AR Kemper","year":"2014","unstructured":"Kemper AR, Green NS, Calonge N et al (2014) Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US department of health and human services Secretary\u2019s advisory committee on heritable disorders in newborns and children. Genet Med 16(2):183\u2013187","journal-title":"Genet Med"},{"key":"788_CR37","doi-asserted-by":"crossref","unstructured":"Liu S, Zhang Y, Deng Z et al (2023) Delayed Biotin Therapy in a Child with Atypical Profound Biotinidase Deficiency: Late Arrival of the Truth and a Lesson Worth Thinking. Int J Mol Sci 24(12)","DOI":"10.3390\/ijms241210239"},{"key":"788_CR38","unstructured":"Loeber JG, Platis D, Zetterstrom RH et al (2021) Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. Int J Neonatal Screen 7(1)"},{"key":"788_CR39","doi-asserted-by":"publisher","first-page":"100714","DOI":"10.1016\/j.lanepe.2023.100714","volume":"33","author":"S Lombardo","year":"2023","unstructured":"Lombardo S, Seedat F, Elliman D et al (2023) Policy-making and implementation for newborn bloodspot screening in Europe: a comparison between EURORDIS principles and UK practice. Lancet Reg Health Eur 33:100714","journal-title":"Lancet Reg Health Eur"},{"key":"788_CR40","unstructured":"Mackie A (2023) Evaluation of NHS newborn screening for SCID extended to March 2024. Available at: https:\/\/nationalscreening.blog.gov.uk\/2023\/06\/13\/evaluation-of-nhs-newborn-screening-for-scid-extended-to-march-2024\/#:~:text=The%20NHS%20invites%20and%20screens,were%20referred%20with%20abnormal%20results. Accessed 30\/11\/2023"},{"issue":"11","key":"788_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jmedgenet-2018-105396","volume":"55","author":"L Mestek-Boukhibar","year":"2018","unstructured":"Mestek-Boukhibar L, Clement E, Jones WD et al (2018) Rapid paediatric sequencing (RaPS): comprehensive real-life workflow for rapid diagnosis of critically ill children. J Med Genet 55(11):721\u2013728","journal-title":"J Med Genet"},{"key":"788_CR42","doi-asserted-by":"crossref","unstructured":"Murch OJJ, Halstead J et al (2021) 1165 The Wales infants\u2019 and children\u2019s genome service\u2019 (WINGS): diagnostic rapid whole genome sequencing for unwell children with a suspected rare genetic diagnosis. Arch Dis Child 106","DOI":"10.1136\/archdischild-2021-rcpch.445"},{"key":"788_CR43","unstructured":"National Screening Unit (2014) Newborn metabolic screening programme - heel prick test Available at: https:\/\/www.health.govt.nz\/your-health\/pregnancy-and-kids\/first-year\/first-6-weeks\/health-checks-first-6-weeks\/newborn-screening-tests\/newborn-metabolic-screening"},{"issue":"2","key":"788_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A et al (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 28(2):165\u2013173","journal-title":"Eur J Hum Genet"},{"key":"788_CR45","unstructured":"Online Mendelian Inheritance in Man (OMIM) (2023) Biotinidase Deficiency Online Mendelian Inheritance in Man"},{"key":"788_CR46","unstructured":"Page T (2023) 100,000 newborn babies will have their genomes sequenced in the UK. It could have big implications for child medicine. CNN Health https:\/\/edition.cnn.com\/2023\/03\/19\/health\/newborn-genomes-programme-uk-genomics-scn-spc-intl\/index.html"},{"key":"788_CR47","unstructured":"Parry V (2023) Which conditions will we look for initially in the generation. Study? Genomics England Website"},{"key":"788_CR48","doi-asserted-by":"publisher","first-page":"866168","DOI":"10.3389\/fgene.2022.866168","volume":"13","author":"A Pichini","year":"2022","unstructured":"Pichini A, Ahmed A, Patch C et al (2022) Developing a National newborn genomes program: an approach driven by ethics, engagement and Co-design. Front Genet 13:866168","journal-title":"Front Genet"},{"key":"788_CR49","unstructured":"Queen Mary University of London (2022) UK Government launches Newborn Genomes Programme"},{"key":"788_CR50","unstructured":"Salova M, Bachman S (2025) Newborn screening: landscape and rare disease developments. Available at: https:\/\/avalere.com\/insights\/newborn-screening-landscape-and-rare-disease-developments"},{"key":"788_CR51","unstructured":"Science Media Center (2022) expert reaction to launch of the newborn whole genome sequencing pilot programme. Available at: https:\/\/www.sciencemediacentre.org\/expert-reaction-to-launch-of-the-newborn-whole-genome-sequencing-pilot-programme\/"},{"key":"788_CR52","unstructured":"Seedat FLS (2022) Meeting the challenges of rare diseases in NHS newborn blood spot screening. Available at: https:\/\/nationalscreening.blog.gov.uk\/2022\/07\/19\/meeting-the-challenges-of-rare-diseases-in-nhs-newborn-blood-spot-screening\/. Accessed 2023."},{"key":"788_CR53","first-page":"33","volume":"5","author":"E Szymanska","year":"2015","unstructured":"Szymanska E, Sredzinska M, Lugowska A et al (2015) Outcomes of oral biotin treatment in patients with biotinidase deficiency - Twenty years follow-up. Mol Genet Metab Rep 5:33\u201335","journal-title":"Mol Genet Metab Rep"},{"issue":"10398","key":"788_CR54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0140-6736(23)01513-1","volume":"402","author":"The Lancet","year":"2023","unstructured":"The Lancet (2023) Genomic newborn screening: current concerns and challenges. Lancet 402(10398):265","journal-title":"Lancet"},{"key":"788_CR55","doi-asserted-by":"crossref","unstructured":"Therrell BL, Padilla CD, Borrajo GJC et al (2024) Current status of newborn bloodspot screening worldwide 2024: A comprehensive review of recent activities (2020\u20132023). Int J Neonatal Screen 10(2)","DOI":"10.3390\/ijns10020038"},{"key":"788_CR56","unstructured":"UK Health Security Agency (2018) In: Why we need to count the people who have rare diseases. Available at: https:\/\/ukhsa.blog.gov.uk\/2018\/02\/27\/why-we-need-to-count-the-people-who-have-rare-diseases\/. Accessed 2023."},{"key":"788_CR57","unstructured":"United Kindgom Government (2022a) Over \u00a3175 million for cutting-edge genomics research. Online"},{"key":"788_CR66","unstructured":"United Kingdom National Screening Committee (2022) Criteria for a population screening programme. Available at: https:\/\/www.gov.uk\/government\/publications\/evidence-review-criteria-national-screening-programmes\/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme"},{"key":"788_CR65","unstructured":"United Kingdom National Screening Committee (2021) 25 years on: how the UK NSC has transformed screening for the better. In: Available at: https:\/\/phescreening.blog.gov.uk\/2021\/07\/30\/25-years-on-how-the-uk-nsc-has-transformed-screening-for-the-better\/. Accessed 2023."},{"key":"788_CR63","unstructured":"United Kingdom National Screening Committee (2019) Generation genome and the opportunities for screening programmes"},{"key":"788_CR59","unstructured":"United Kingdom Government (2022) UK NSC blood spot task group (BSTG). Available at: https:\/\/www.gov.uk\/government\/groups\/uk-nsc-blood-spot-task-group-bstg"},{"key":"788_CR58","unstructured":"United Kindgom Government (2022b) UK National Screening Committee - About us. Available at: https:\/\/www.gov.uk\/government\/organisations\/uk-national-screening-committee\/about"},{"key":"788_CR60","unstructured":"United Kingdom Government Department of Health (2013) The UK Strategy for Rare Diseases"},{"key":"788_CR61","unstructured":"United Kingdom Government Department of Health (2023) England Rare Diseases Action Plan 2023: main report"},{"key":"788_CR62","unstructured":"United Kingdom National Screening Committee (1998) National Screening Committee. First report of the National Screening Committee. In: Kingdom HDotU (ed)"},{"key":"788_CR68","unstructured":"United Kingdom National Screening Committee (2023b) UK NSC Blood Spot Task Group July 2023 meeting summary. Available at: https:\/\/www.gov.uk\/government\/publications\/uk-nsc-blood-spot-task-group-july-2023-meeting-summary"},{"key":"788_CR64","unstructured":"United Kingdom National Screening Committee, UK National Screening Committee (UK NSC) (2020): Note of the meeting held on the 26 February 2020 at Park Plaza London Riverbank, 18 Albert Embankment, London, SE1 7TJ."},{"key":"788_CR67","unstructured":"United Kingdom National Screening Committee (2023a) UK NSC annual call: submitting a screening proposal"},{"key":"788_CR69","unstructured":"Wolf B (1993) Biotinidase Deficiency. In: Adam MP, Mirzaa GM, Pagon RA, (eds) GeneReviews((R)). Seattle (WA)"},{"issue":"4","key":"788_CR70","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/gim.2016.135","volume":"19","author":"B Wolf","year":"2017","unstructured":"Wolf B (2017) Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening. Genet Med 19(4):396\u2013402","journal-title":"Genet Med"},{"issue":"1","key":"788_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM198507043130104","volume":"313","author":"B Wolf","year":"1985","unstructured":"Wolf B, Heard GS, Jefferson LG et al (1985) Clinical findings in four children with biotinidase deficiency detected through a statewide neonatal screening program. N Engl J Med 313(1):16\u201319","journal-title":"N Engl J Med"},{"issue":"4","key":"788_CR72","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clindermatol.2020.03.004","volume":"38","author":"Y Yang","year":"2020","unstructured":"Yang Y, Yang JY, Chen XJ (2020) Biotinidase deficiency characterized by skin and hair findings. Clin Dermatol 38(4):477\u2013483","journal-title":"Clin Dermatol"}],"container-title":["Journal of Community Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12687-025-00788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12687-025-00788-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12687-025-00788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:14:22Z","timestamp":1757186062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12687-025-00788-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s12687-025-00788-1","relation":{},"ISSN":["1868-6001"],"issn-type":[{"value":"1868-6001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any human participants. Consequently, no consent for participation was required or obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}